Trevena Q4 2020 Earnings Report
Key Takeaways
Trevena, Inc. reported a net loss attributable to common stockholders of $11.9 million, or $0.08 per share, for the fourth quarter of 2020. Year-end cash and cash equivalents were $109.4 million as of December 31, 2020, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through the fourth quarter of 2022.
OLINVYKâ„¢ approved in U.S.; customer-facing teams now fully deployed
Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021
IND for TRV045 (S1P1 receptor modulator) on track for 1H 2021; focus in epilepsy and neuropathic pain
Year-end cash of $109.4M funds operations through YE 2022
Trevena
Trevena
Trevena Revenue by Segment
Forward Guidance
The Company believes that cash and cash equivalents of $109.4 million as of December 31, 2020, will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through the fourth quarter of 2022.